AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02485678 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proactive Telephone Toxicity Management
Description: Centres randomized to this arm will implement a pro-active telephone toxicity management program, for all eligible early stage breast cancer patients beginning neo-adjuvant or adjuvant chemotherapy within the intervention period until the end of their systemic treatment. Patients will receive a phone call from a local nurse who has been trained on the toxicity management toolkit at 24-72 hours and at 8 to 10 days following each chemotherapy administration. The provider conducting the call will be provided with a script and will complete the Telephone Follow-Up Questionnaire which includes questions from the abbreviated NCI PRO-CTCAE tool. The nurse conducting the call will also be provided with the provider version of the symptom management booklet and provide toxicity management counseling. If any toxicity-related problems are identified during the call, a second call will take place 24 hours after the initial call to ensure the problem is resolving or to provide additional support.
Study NCT02485678 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Arm
Description: Centres randomized to the control arm will continue to provide routine care for chemotherapy-related toxicities as is the current standard in the centre.
Study NCT02485678 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PRO Sub-Study
Description: A sub-set of approximately 25 patients enrolled at each participating centre will participate in a Patient Reported Outcomes (PRO) sub-study to assess the effect of the intervention on secondary outcomes.
Study NCT02485678 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRO Sub-Study
Description: A sub-set of approximately 25 patients enrolled at each participating centre will participate in a Patient Reported Outcomes (PRO) sub-study to assess the effect of the intervention on secondary outcomes.
Study NCT00278408 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: filgrastim
Study NCT00278408 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Study NCT00278408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: cyclophosphamide
Study NCT00278408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: doxorubicin hydrochloride
Study NCT00278408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prednisone
Study NCT00278408 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: vincristine sulfate
Study NCT00278408 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: radiation therapy
Study NCT00278915 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: Participants will receive intramuscular injection of fulvestrant as stated in arm description.
Study NCT02780323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CELBESTA®
Description: 1 tablet of CELBESTA® and 1 tablet of CELEBREX® placebo, twice daily for 6 weeks
Study NCT02780323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CELEBREX®
Description: 1 tablet of CELEBREX® and 1 tablet of CELBESTA® placebo, twice daily for 6 weeks
Study NCT02780323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CELEBREX® placebo
Description: 1 tablet of CELBESTA® and 1 tablet of CELEBREX® placebo, twice daily for 6 weeks
Study NCT02780323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CELBESTA® placebo
Description: 1 tablet of CELEBREX® and 1 tablet of CELBESTA® placebo, twice daily for 6 weeks
Study NCT04592263 — intervention group
Intervention type: OTHER
Intervention: EPD Questionnaire
Description: A 44 items questionnaire (4 point likert scale) was distributed. Included dimensions where: experience with your physician, provision of care, barriers, outcomes of care, symptoms, patient engagement, health literacy and patient empowerment.
Study NCT04173793 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AK102
Description: Administered by subcutaneous injection
Study NCT03059628 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Brief Therapeutic Intervention
Description: BTI are brief (typically one session 20-30 mns) and incorporate some or all of the following elements:feedback on the person's alcohol use and any alcohol-related harm; clarification as to what constitutes low risk alcohol consumption; information on the harms associated with risky alcohol use; benefits of reducing intake; motivational enhancement; analysis of high risk situations for drinking and coping strategies; and the development of a personal plan to reduce consumption.
Study NCT04020744 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: real-time fMRI based neurofeedback from another brain area
Description: During real-time fMRI neurofeedback, participants are trained to 'control' hippocampal activity. The training is accomplished by continuously measuring brain activity, analysing it in real-time, and then providing feedback about the current (and the targeted) brain activity to the participant.
Study NCT03059628 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Brief Therapeutic Intervention
Description: BTI are brief (typically one session 20-30 mns) and incorporate some or all of the following elements:feedback on the person's alcohol use and any alcohol-related harm; clarification as to what constitutes low risk alcohol consumption; information on the harms associated with risky alcohol use; benefits of reducing intake; motivational enhancement; analysis of high risk situations for drinking and coping strategies; and the development of a personal plan to reduce consumption.
Study NCT03059628 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Evaluation questionnaire
Description: The patient have to fill the same evaluation questionnaire at J0, M6 and M12
Study NCT03059628 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Evaluation questionnaire
Description: The patient have to fill the same evaluation questionnaire at J0, M6 and M12
Study NCT00613145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine and Sorafenib
Description: During Cycle 1, patients will receive capecitabine alone for the first 7 days (Cohort A will receive 750 mg/m2 of capecitabine twice daily). For Days 8-14 of Cycle 1, patients will receive capecitabine (750 mg/m2 twice daily for Cohort A) combined with sorafenib (400 mg twice daily); on Days 15-21 of Cycle 1, patients will receive sorafenib alone (400 mg twice daily). Beginning with Day 1 of Cycle 2 and all treatment cycles thereafter, patients will be dosed as follows:~Cohort A will receive sorafenib orally at 400 mg twice daily for 21 days, and capecitabine orally at 750 mg/m2 twice daily for the first 14 days of a 21-day treatment cycle.
Study NCT00613145 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine and Sorafenib
Description: During Cycle 1, patients will receive capecitabine alone for the first 7 days Cohort B will receive 1000 mg/m2 of capecitabine twice daily for the first 7 days of Cycle 1). For Days 8-14 of Cycle 1, patients will receive capecitabine (1000 mg/m2 twice daily for Cohort B) combined with sorafenib (400 mg twice daily for both cohorts); on Days 15-21 of Cycle 1, patients will receive sorafenib alone (400 mg twice daily). Beginning with Day 1 of Cycle 2 and all treatment cycles thereafter, patients will be dosed as follows: Cohort B will receive sorafenib orally at 400 mg twice daily for 21 days, and capecitabine orally at 1000 mg/m2 twice daily for the first 14 days of a 21-day treatment cycle.
Study NCT02045563 — intervention group
Intervention type: OTHER
Intervention: prise de sang
Study NCT02045563 — intervention group
Intervention type: OTHER
Intervention: magnetic resonance imaging and magnetic resonance spectroscopy
Study NCT04395586 — intervention group
Intervention type: OTHER
Intervention: Culture
Description: Culture
Study NCT03871907 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Digital technology
Description: Lifestyle-Focused Text Messaging
Study NCT03614845 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: VCV
Description: after induction for anesthesia patients will be supported by mechanical ventilation on volume controlled ventilation mode
Study NCT03614845 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PCV-VG
Description: after induction for anesthesia patients will be supported by mechanical ventilation on pressure controlled and volume guaranteed ventilation mode
Study NCT03614845 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: lung ultrasonography
Description: all patients will be performed lung ultrasonography pre and postoperatively
Study NCT03161405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAK-906 Maleate
Description: TAK-906 capsule
Study NCT03161405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Itraconazole solution
Study NCT03697798 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Boostrix®-IPV combination vaccine
Description: A licensed aP (acellular) booster vaccine developed by GlaxoSmithKline.
Study NCT02631772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir/Ledipasvir x 12 weeks
Study NCT02631772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sofosbuvir/Ledipasvir + Ribavirin x 12 weeks
Study NCT03914183 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: mCPN Intervention
Description: Each box of montméd Coloured Pen Needles (mCPN) has the following five features:~i. Distinctively coloured pen needles ii. A user-defined association tool which is intended to help the patient associate each colour to a specific injection zone iii. A concise and intuitive educational message Change color, change site siteTM iv. Unique packaging with educational content v. Four distinctive message-in-a-box educational sound-chips which serve to reinforce the recommended educational message on site rotation at home and come on every tenth time the pen needle box is opened
Study NCT03914183 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Control
Description: Use of standard of care insulin pen needle
Study NCT04027205 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physiotherapist-led exercise
Description: A programme of physiotherapist-led exercise over approximately 12 weeks.
Study NCT04027205 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgical repair
Description: Surgical repair of the rotator cuff plus usual post-operative rehabilitation
Study NCT00626184 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 4 dose levels of ALV003
Description: 4 dose levels of ALV003 vs placebo
Study NCT00626184 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4 dose levels of ALV003
Description: 4 dose levels of ALV003 vs placebo
Study NCT02386618 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Standardized endoscopic treatment of local residual neoplasia
Description: Endoscopic treatment will be performed according to the type of local residual neoplasia (LRN): A - endoscopically negative scar and neoplastic tissue found only in biopsy specimens - treatment by argon plasmacoagulation, B - endoscopically aparent LRN \< 5 mm - forceps biopsy + argon plasmacoagulation, C - endoscopically evident LRN > 5 mm + lifting during submucosal injection - endoscopic mucosal resectio + argon plasmacoagulation, D - endoscopically evident LRN > 5 mm + non-lifting during submucosal injection - endoscopic submucosal disection (ESD) or surgical resection
Study NCT01504763 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Chair massage
Description: Chair massage for 15 minutes once a week for 10 weeks.
Study NCT03024515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: opioids titration
Description: Standard Practice Arm
Study NCT03024515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: predefined titration steps
Description: comprising of oxycodone immediate release (OXYNORM) and oxycodone sustained release (OXYCONTIN) in pre-defined doses and frequencies
Study NCT03951363 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: interactive Obesity Treatment Approach (iOTA)
Description: The investigators will adapt an evidence-based digital health intervention to promote adherence to nationally recommended diet and physical activity guidelines for patients with chronic kidney disease. The intervention includes goal assignment, goal tracking, and skills training messages.
Study NCT01691456 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast sodium
Description: Montelukast Sodium Oral Granules 4mg
Study NCT01691456 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Montelukast sodium
Description: Montelukast Sodium Oral Granules 4mg
Study NCT04737486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AV-001
Description: AV-001 (mpaBr) Cl for Injection 2.5 mg/mL
Study NCT04737486 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: D-PBS
Study NCT00264394 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Updated CHD risk profiles
Description: Provision of computer generated CHD risk profiles
Study NCT00264394 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Guidelines
Description: provision of guidelines for CHD risk factor management only
Study NCT01922921 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: HER-2/neu Intracellular Domain Protein
Description: Given ID
Study NCT01922921 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HER-2/neu Intracellular Domain Protein
Description: Given ID
Study NCT01581658 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI10773
Description: BI10773 medium dose tablet single dose
Study NCT01922921 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01577381 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: RN6G
Description: Intravenous, 11 doses, 30 minute infusion, dose ranging from 2.5 mg/kg up to a maximum of 15 mg/kg
Study NCT01577381 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous, 11 doses, 30 minute infusion
Study NCT02096991 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Can 1
Description: drink the beverage in a can and a glass bottle
Study NCT02096991 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Can 1
Description: drink the beverage in a can and a glass bottle
Study NCT02096991 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Can 2
Description: Consume two canned beverage
Study NCT02096991 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Can 2
Description: Consume two canned beverage
Study NCT02096991 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glass
Description: consume two glass bottled beverage
Study NCT02096991 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glass
Description: consume two glass bottled beverage
Study NCT01074203 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nitazoxanide
Description: Drug administration: The drug will be available through the research pharmacy. Patients will receive 1000mg (2 tablets) oral NTZ or an equivalent dose of NTZ suspension 1500mg (75mL) according to the schedule below.~Dose timing Dose Schedule Interval Dose Pre-transplant(on admission) 1000mg oral Once Total 1 dose Pre-transplant (delayed surgery >12 hours) 1000mg oral Every 12 hrs Variable Post operative dose 1000mg oral/ nasogastric tube Every 12 hrs Total 6 doses~All attempts will be made to administer the tablet form of the medication, given the higher area under the curve that is achieved. If needed, the suspension formulation will be used. Since the suspension form has 70% bioavailability, the suspension dose administered will be 1.5 grams every 12 hours until the tablet form can be given.
Study NCT04044521 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Systems consultation
Description: Systems consultation consists of three implementation strategies: academic detailing (AD), practice facilitation (PF), and physician peer consulting (PPC). Clinics will receive a combination of these strategies for 21 months.~AD: Clinicians will attend an educational meeting that will detail the study and Center for Disease Control guidelines for opioid prescribing in primary care. Clinicians will then will get a monthly audit \& feedback report on their prescribing.~PF: clinics will be randomized to receive practice facilitation. Facilitators will meet with each clinic. Facilitators walk through the clinic, identify areas of opioid prescribing workflow improvement, conduct a nominal group technique with the change team, and set a Plan-Do-Study-Act cycle. Clinics will follow-up with the facilitators monthly.~PPC: Clinicians of the clinics will meet quarterly with the physician peer consultant to discuss tough patient cases and panels regarding opioid prescribing.
Study NCT03981445 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: ARTAS Adapted Patient Navigation
Description: Patient navigation will provided by trained patient navigators to participants randomized to the off-site referral to specialized care arm. Patient Navigators will actively coordinate and link participants to available clinics and community resources by scheduling appointments, arranging transportation, and assisting the participant with completing any paperwork that a clinic or service agent may require. The intervention will include up to five, 30-45 minute face-to-face meetings between the patient navigator and participant. These meetings will be tailored around each participant's needs. Additionally, the patient navigator assists the participant in identifying and utilizing informal and formal sources of support to move along the PrEP and/or HCV care continuum.The patient navigator will help the participant inform off-site physicians of the trial and of the availability of PrEP and HCV medication, should the physician and patient decide to initiate one or both treatments.
Study NCT01922921 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01922921 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Pertuzumab
Description: Given per standard of care
Study NCT01922921 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pertuzumab
Description: Given per standard of care
Study NCT01922921 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Given PO
Study NCT01922921 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Polysaccharide-K
Description: Given PO
Study NCT01922921 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: Given per standard of care
Study NCT01922921 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: Given per standard of care
Study NCT01914679 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: RINCE
Description: The intervention is repeat applications of RINCE therapy. The sham is created by not delivering the therapy stimulation signal.
Study NCT00459030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention via internet
Description: additional cancer screening information via password protected internet site
Study NCT00459030 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: educational intervention mailed
Study NCT00459030 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No additional educational intervention
Study NCT02354833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phenylephrine
Study NCT02354833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Norepinephrine
Study NCT01548261 — intervention group
Intervention type: PROCEDURE
Intervention: Donating oral mucosal cells
Description: Donating oral mucosal cells
Study NCT04255511 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Twin Block
Description: Functional appliance
Study NCT04255511 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fixed orthodontic appliance
Description: Braces
Study NCT00282243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus modified release (MR)
Description: Oral
Study NCT00282243 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tacrolimus
Description: Oral
Study NCT00496366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: The dose of capecitabine is 1000 mg/m2/dose twice each day, orally, 12 hours apart, for 14 consecutive days, every 21 days (total daily dose = 2000 mg/m2).
Study NCT00496366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib
Description: The daily dose of lapatinib is 1250 mg (5 tablets of 250 mg each) to be taken at approximately the same time each day, continuously. Lapatinib is taken even during the week that capecitabine is not taken.